Liquidia Technologies’ planned acquisition of RareGen in Q4 will be a significant opportunity for Liquidia to expand its rare diseases pipeline, bolster its pulmonary arterial hypertension (PAH) drug portfolio and establish the new company as a strong player in the space, according to GlobalData, a leading data and analytics company.

Despite the availability of multiple treatment options in the PAH market such as endothelin receptor antagonists (ERAs), PDE5 inhibitors, soluble guanylyl cyclase (sGC) stimulators and prostacyclin derivatives, it remains a space with high clinical unmet need. Furthermore, key opinion leaders interviewed by GlobalData have emphasized that PAH drugs have generally been quite pricey but now cheaper options are opening up for patients due to the availability of generics.

Kajal Jaddoo, Associate Pharma Analyst at GlobalData, comments: “The acquisition will give Liquidia the right to promote RareGen and Sandoz’s first injectable generic version of Remodulin (treprostinil) for treating PAH. Due to its generic status, Liquidia can price generic Remodulin significantly cheaper than all available alternatives in what is a price conscious and emerging market.”

“Through this acquisition, Liquidia will have a significant opportunity to maximize the commercial potential of LIQ-861 and generic Remodulin with the support of RareGen’s PAH-focused sales force and experienced strategy and investment teams. As the company’s leading product, LIQ-861’s

clinical development is significant because of its less cumbersome dosing administration than the currently available PAH treatment options.

“This acquisition is a good strategic fit for Liquidia, as it is an opportunity for the company to broaden its PAH pipeline through the support of RareGen’s specialist- strategy, investment, and commercialization teams. In addition, Liquidia Corporation will be able to advance much needed therapy options for the PAH patients.”